Cargando…
HMGB1 in Radiotherapy: A Two Headed Signal Regulating Tumor Radiosensitivity and Immunity
Radiotherapy (RT) is a mainstay of cancer treatment. Recent studies have shown that RT not only directly induces cell death but also has late and sustained immune effects. High mobility group box 1 (HMGB1) is a nuclear protein released during RT, with location-dependent functions. It is essential fo...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7369309/ https://www.ncbi.nlm.nih.gov/pubmed/32764978 http://dx.doi.org/10.2147/OTT.S253772 |
_version_ | 1783560754402689024 |
---|---|
author | Liao, Yin Liu, Shuya Fu, Shaozhi Wu, Jingbo |
author_facet | Liao, Yin Liu, Shuya Fu, Shaozhi Wu, Jingbo |
author_sort | Liao, Yin |
collection | PubMed |
description | Radiotherapy (RT) is a mainstay of cancer treatment. Recent studies have shown that RT not only directly induces cell death but also has late and sustained immune effects. High mobility group box 1 (HMGB1) is a nuclear protein released during RT, with location-dependent functions. It is essential for normal cellular function but also regulates the proliferation and migration of tumor cells by binding to high-affinity receptors. In this review, we summarize recent evidence on the functions of HMGB1 in RT according to the position, intracellular HMGB1 and extracellular HMGB1. Intracellular HMGB1 induces radiation tolerance in tumor cells by promoting DNA damage repair and autophagy. Extracellular HMGB1 plays a more intricate role in radiation-related immune responses, wherein it not only stimulates the anti-tumor immune response by facilitating the recognition of dying tumor cells but is also involved in maintaining immunosuppression. Factors that potentially affect the role of HMGB1 in RT-induced cytotoxicity have also been discussed in the context of possible therapeutic applications, which helps to develop effective and targeted radio-sensitization therapies. |
format | Online Article Text |
id | pubmed-7369309 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Dove |
record_format | MEDLINE/PubMed |
spelling | pubmed-73693092020-08-05 HMGB1 in Radiotherapy: A Two Headed Signal Regulating Tumor Radiosensitivity and Immunity Liao, Yin Liu, Shuya Fu, Shaozhi Wu, Jingbo Onco Targets Ther Review Radiotherapy (RT) is a mainstay of cancer treatment. Recent studies have shown that RT not only directly induces cell death but also has late and sustained immune effects. High mobility group box 1 (HMGB1) is a nuclear protein released during RT, with location-dependent functions. It is essential for normal cellular function but also regulates the proliferation and migration of tumor cells by binding to high-affinity receptors. In this review, we summarize recent evidence on the functions of HMGB1 in RT according to the position, intracellular HMGB1 and extracellular HMGB1. Intracellular HMGB1 induces radiation tolerance in tumor cells by promoting DNA damage repair and autophagy. Extracellular HMGB1 plays a more intricate role in radiation-related immune responses, wherein it not only stimulates the anti-tumor immune response by facilitating the recognition of dying tumor cells but is also involved in maintaining immunosuppression. Factors that potentially affect the role of HMGB1 in RT-induced cytotoxicity have also been discussed in the context of possible therapeutic applications, which helps to develop effective and targeted radio-sensitization therapies. Dove 2020-07-14 /pmc/articles/PMC7369309/ /pubmed/32764978 http://dx.doi.org/10.2147/OTT.S253772 Text en © 2020 Liao et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). |
spellingShingle | Review Liao, Yin Liu, Shuya Fu, Shaozhi Wu, Jingbo HMGB1 in Radiotherapy: A Two Headed Signal Regulating Tumor Radiosensitivity and Immunity |
title | HMGB1 in Radiotherapy: A Two Headed Signal Regulating Tumor Radiosensitivity and Immunity |
title_full | HMGB1 in Radiotherapy: A Two Headed Signal Regulating Tumor Radiosensitivity and Immunity |
title_fullStr | HMGB1 in Radiotherapy: A Two Headed Signal Regulating Tumor Radiosensitivity and Immunity |
title_full_unstemmed | HMGB1 in Radiotherapy: A Two Headed Signal Regulating Tumor Radiosensitivity and Immunity |
title_short | HMGB1 in Radiotherapy: A Two Headed Signal Regulating Tumor Radiosensitivity and Immunity |
title_sort | hmgb1 in radiotherapy: a two headed signal regulating tumor radiosensitivity and immunity |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7369309/ https://www.ncbi.nlm.nih.gov/pubmed/32764978 http://dx.doi.org/10.2147/OTT.S253772 |
work_keys_str_mv | AT liaoyin hmgb1inradiotherapyatwoheadedsignalregulatingtumorradiosensitivityandimmunity AT liushuya hmgb1inradiotherapyatwoheadedsignalregulatingtumorradiosensitivityandimmunity AT fushaozhi hmgb1inradiotherapyatwoheadedsignalregulatingtumorradiosensitivityandimmunity AT wujingbo hmgb1inradiotherapyatwoheadedsignalregulatingtumorradiosensitivityandimmunity |